[HTML][HTML] Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine

Y Nomura, M Sawahata, Y Nakamura, M Kurihara… - Vaccines, 2021 - mdpi.com
Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the
BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables …

Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia

…, S Ikushima, T Ando, M Oritsu, M Sawahata… - …, 2012 - Wiley Online Library
Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, Sawahata M & Ogura T (2012)
Histopathology Pathological differentiation of chronic hypersensitivity pneumonitis from …

[HTML][HTML] Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan

M Sawahata, Y Sugiyama, Y Nakamura… - Respiratory …, 2015 - Elsevier
Background National surveys conducted in Japan between 1960 and 2004 suggest a gradually
increasing incidence of sarcoidosis in women >50 years old with increased involvement …

[HTML][HTML] Attenuation of antibody titers from 3 to 6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking risk factors for lower …

Y Nomura, M Sawahata, Y Nakamura, R Koike… - Vaccines, 2021 - mdpi.com
Objective: We aimed to determine antibody titers at six months and their percentage change
from three to six months after the second dose of the BNT162b2 coronavirus disease 2019 (…

[HTML][HTML] The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study

…, I Strambu, J Francesqui, J Sellares, M Sawahata… - Respiratory …, 2021 - Elsevier
Objective To study how demographic differences impact disease manifestation of sarcoidosis
using the WASOG tool in a large multicentric study. Methods Clinical data regarding 1445 …

[PDF][PDF] An epidemiological perspective of the pathology and etiology of sarcoidosis

M Sawahata, Y Sugiyama - Sarcoidosis Vasc Diffuse Lung Dis, 2016 - researchgate.net
To update current knowledge on the pathology and etiology of sarcoidosis, here we review
previous epidemiological research and discuss age-related differences and historical …

[HTML][HTML] Computed tomography images of fibrotic pulmonary sarcoidosis leading to chronic respiratory failure

M Sawahata, T Johkoh, T Kawanobe, C Kono… - Journal of Clinical …, 2020 - mdpi.com
Background: There is currently no consensus on the morphology of severe fibrotic pulmonary
sarcoidosis, and we examined computed tomography (CT) findings and progression. …

[HTML][HTML] Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination

R Koike, M Sawahata, Y Nakamura, Y Nomura… - Vaccines, 2022 - mdpi.com
Objective: We aimed to determine the relationship between vaccine-related adverse effects
and antibody (Ab) titers from 3 to 6 months after the second dose of the BNT162b2 …

Pulmonary mycobacteriosis caused by Mycobacterium peregrinum in a young, healthy man

M Sawahata, E Hagiwara, T Ogura… - Nihon Kokyuki Gakkai …, 2010 - europepmc.org
A 24-year-old male never-smoker with no contributory medical history was referred to our
division because of chronic productive cough and fever. His chest CT showed pulmonary …

[HTML][HTML] Imaging findings of fibrosis in pulmonary sarcoidosis

M Sawahata, T Yamaguchi - Sarcoidosis, Vasculitis, and Diffuse …, 2022 - ncbi.nlm.nih.gov
Background: In pulmonary sarcoidosis, respiratory tract lesions almost always appear, and
residual lung shadows require treatment in about 20% of cases. Pulmonary fibrosis is among …